简介:一元复始,万象更新,值此新年到来之际,我谨代表世界中医药学会联合会(以下简称“世界中联),向世界中联全体会员致以诚挚的问候,向关心和支持世界中联事业发展的世界各国中医药团体致以崇高的敬意和新年的祝福!向一直关注和支持中医药事业发展的各界领导和专家、学者、同仁们表示衷心地感谢!祝大家在新的一年里生活幸福,工作顺利,平安吉祥!
简介:Over20yearsofresearchhasledtothenowwidelyacceptedroleofcardiacresynchronizationtherapy(CRT)inmedicallyrefractory,mildtoseveresystolicheartfailure(HF)withincreasedQRSduration.Inadditiontoconferringamortalitybenefit,CRThasbeenshowntoreduceHFhospitalizationratesandimprovefunctionalstatusinthispopulation.However,notallpatientsconsistentlydemonstrateapositiveresponsetoCRT.EffortstoimproveresponsetoCRThavefocusedonimprovingpatientselectionandoptimizingdeviceimplantationandfollow-up,therebycorrectingelectricalandmechanicaldyssynchrony.Inthisarticlewereviewthepathobiologyofcardiacdyssynchrony,therationalefortheuseofCRT,thehistoryandthestateoftheartofCRT,andguidelinesandrecommendationsforCRT,whilealsofocusingontheareasofcontroversyandpotentialfutureapplications.
简介:Personalizedcancermedicinehasseensignificantimprovementsoverthepastdecade.RecentElsevierconference:Miamiwintersymposium2015(MWS2015)'TowardsPersonalizedCancerMedicine'meetingwasdedicatedtothisexcitingfield,andfocusedonnewprogressinpersonalizeddrugdevelopmentandantibodydrugagainstcheckpointpathway.Thismeetingreportsummarizesthekeydevelopmentspresentedanddiscussedatthemeeting,withafocusonimmunotherapy,especiallyontheCTLA-4andPD-1/PD-L1pathways.Themonoclonalantibodydrugsinterveningthesecheckpointpathwayshavethepotentialtoplayalargerroleinpersonalizemedicinewithinthenearfuture.Hereweintendedtoprovideacomprehensivesummaryaboutongoingtrendsandfutureperspectivesonpersonalizedmedicineincancertherapy.